[go: up one dir, main page]

AR073770A1 - Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden - Google Patents

Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden

Info

Publication number
AR073770A1
AR073770A1 ARP090103832A ARP090103832A AR073770A1 AR 073770 A1 AR073770 A1 AR 073770A1 AR P090103832 A ARP090103832 A AR P090103832A AR P090103832 A ARP090103832 A AR P090103832A AR 073770 A1 AR073770 A1 AR 073770A1
Authority
AR
Argentina
Prior art keywords
fgfr
human
seq
sequence
receptor
Prior art date
Application number
ARP090103832A
Other languages
English (en)
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of AR073770A1 publication Critical patent/AR073770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpo aislado que se enlaza específicamente con el receptor-3 del factor de crecimiento del fibroblasto humano (FGFR-3) (III b) y FGFR-3 (III c) o de formas mutantes de FGFR-3 e induce la degradacion de dicho receptor. Comprende una CDRH1 que tiene la secuencia GYMFTSYGIS (SEC ID Ns:1), una CDRH2 que tiene la secuencia WVSTYNGDTNYAQKFQG (SEC ID Ns: 2), un CDRH3 que tiene la secuencia VLGYYDSIDGYYYGMDV (SEC ID Ns: 3), una CDRL1 que tiene le secuencia GGNNIGDKSVH (SEC ID Ns: 4), una CDRL2 que tiene la secuencia LDTERPS (SEC. ID Ns: 5), y una CDRL3 que tiene la secuencia QVWDSGSDHVV (SEC ID Ns: 6). Fragmento de enlace FGFR-3 humano de dicho anticuerpo. Composicion farmacéutica que lo comprende. Producto que contiene dicho anticuerpo o fragmento. Su uso como medicamento para tratar cáncer.
ARP090103832A 2008-10-20 2009-10-05 Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden AR073770A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20

Publications (1)

Publication Number Publication Date
AR073770A1 true AR073770A1 (es) 2010-12-01

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103832A AR073770A1 (es) 2008-10-20 2009-10-05 Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden

Country Status (17)

Country Link
US (3) US8043618B2 (es)
EP (1) EP2342232A2 (es)
JP (1) JP5577345B2 (es)
KR (1) KR101370798B1 (es)
CN (2) CN102186884B (es)
AR (1) AR073770A1 (es)
AU (1) AU2009307841B2 (es)
BR (1) BRPI0919832A8 (es)
CA (1) CA2741127C (es)
EA (1) EA021584B1 (es)
IL (1) IL211807A0 (es)
MX (1) MX2011004317A (es)
NZ (1) NZ592369A (es)
TW (1) TWI381848B (es)
UA (1) UA101681C2 (es)
WO (1) WO2010048026A2 (es)
ZA (1) ZA201101938B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
DK3702371T5 (da) 2009-03-25 2024-08-26 Genentech Inc Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
KR20160002681A (ko) 2013-01-16 2016-01-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 골격 성장 지연 질환의 예방 또는 치료에 사용하기 위한 용해성 섬유아세포 성장 인자 수용체 3(fgr3) 폴리펩티드
WO2014138364A2 (en) 2013-03-06 2014-09-12 Genentech, Inc. Methods of treating and preventing cancer drug resistance
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
EP3122776B1 (en) 2014-03-25 2021-04-28 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
US20230190750A1 (en) 2014-06-13 2023-06-22 Genentech, Inc. Methods of treating and preventing cancer drug resistance
MX388115B (es) * 2014-09-05 2025-03-19 Hyperfine Res Inc Configuracion automatica de un sistema de formacion de imagenes por resonancia magnetica de campo bajo.
WO2016048833A2 (en) 2014-09-26 2016-03-31 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2016219917B2 (en) * 2015-02-19 2021-12-16 Fusion Pharmaceuticals Inc. Methods, compositions, and kits for treatment of cancer
WO2016139227A1 (en) 2015-03-03 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Fgfr3 antagonists
TW201711702A (zh) 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
HUE058734T2 (hu) 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
WO2018129451A2 (en) * 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
KR20230052963A (ko) 2020-08-21 2023-04-20 젠자임 코포레이션 Fgfr3 항체 및 사용 방법
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
US20240173426A1 (en) * 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
AU2024207469A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
AU2002329540A1 (en) 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7960518B2 (en) * 2006-06-06 2011-06-14 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and uses thereof
EA017203B1 (ru) * 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
US8012474B2 (en) * 2007-08-02 2011-09-06 Nov Immune S.A. Anti-RANTES antibodies
UA121453C2 (uk) * 2008-04-11 2020-06-10 Чугей Сейяку Кабусікі Кайся Спосіб одержання фармацевтичної композиції, яка містить антитіло
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物

Also Published As

Publication number Publication date
US20100098696A1 (en) 2010-04-22
TW201026325A (en) 2010-07-16
CN103524620A (zh) 2014-01-22
AU2009307841B2 (en) 2013-09-12
US20120009200A1 (en) 2012-01-12
WO2010048026A2 (en) 2010-04-29
NZ592369A (en) 2013-02-22
AU2009307841A1 (en) 2010-04-29
BRPI0919832A2 (pt) 2015-12-15
TWI381848B (zh) 2013-01-11
CN102186884A (zh) 2011-09-14
US8043618B2 (en) 2011-10-25
US8404240B2 (en) 2013-03-26
CA2741127A1 (en) 2010-04-29
BRPI0919832A8 (pt) 2019-01-08
CN102186884B (zh) 2014-08-13
EA021584B1 (ru) 2015-07-30
KR101370798B1 (ko) 2014-03-14
ZA201101938B (en) 2012-08-29
EP2342232A2 (en) 2011-07-13
WO2010048026A3 (en) 2010-07-15
CA2741127C (en) 2015-06-02
UA101681C2 (ru) 2013-04-25
MX2011004317A (es) 2011-06-24
US20120219563A1 (en) 2012-08-30
KR20110056554A (ko) 2011-05-30
US8182815B2 (en) 2012-05-22
JP2012505912A (ja) 2012-03-08
JP5577345B2 (ja) 2014-08-20
EA201170590A1 (ru) 2011-10-31
IL211807A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
AR073770A1 (es) Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
AR123305A2 (es) Proteínas de unión a antígeno
ES2631135T3 (es) Proteínas de unión a antígeno humanas que se unen a beta-Klotho, receptores de FGF y complejos de los mismos
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
PE20180927A1 (es) Moleculas de union a lag-3 y metodos de uso de las mismas
ES2430068T3 (es) Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina
PE20191131A1 (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
AR086579A1 (es) Proteinas de union a antigeno
NZ744185A (en) Antibodies and conjugates thereof
CL2010001544A1 (es) Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma.
PE20091674A1 (es) Antagonistas del receptor de glucagon
AR081556A1 (es) Proteinas de union al antigeno humanizadas
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
NZ596274A (en) Blocking anti-dkk-1 antibodies and their uses
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
AR061115A1 (es) Anticuerpos anti- interleuquina 18 (il-18)
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20170687A1 (es) Proteinas de enlace a cd127
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
PE20161033A1 (es) Proteinas de union al antigeno gitr
AR086044A1 (es) Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
WO2012045481A8 (en) Antibody targeting osteoclast-related protein siglec-15
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
NZ610153A (en) Novel anti-dr5 antibody

Legal Events

Date Code Title Description
FB Suspension of granting procedure